|
DE3177213D1
(de)
|
1980-04-03 |
1990-10-18 |
Biogen Inc |
Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
|
|
NZ212645A
(en)
*
|
1984-07-06 |
1990-02-26 |
Sandoz Ltd |
Method for producing primate granulocyte-macrophage colony stimulating factor (gm-csf)
|
|
JPS61227526A
(ja)
*
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
UA29377C2
(uk)
*
|
1984-09-19 |
2000-11-15 |
Новартіс Аг |
Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
|
|
EP0202300B1
(en)
*
|
1984-11-20 |
1992-11-11 |
Schering Biotech Corporation |
Cdna clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity
|
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
|
DE3681551D1
(de)
*
|
1985-09-30 |
1991-10-24 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granulozyten-colony stimulierender faktor.
|
|
JPH0618778B2
(ja)
*
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
|
DE3545568A1
(de)
*
|
1985-12-21 |
1987-07-16 |
Hoechst Ag |
Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
|
|
US5298603A
(en)
*
|
1985-12-21 |
1994-03-29 |
Hoechst Aktiengesellschaft |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
|
|
EP0232707A1
(en)
*
|
1986-01-09 |
1987-08-19 |
Ajinomoto Co., Inc. |
Human hematopoietic cell growth potentiating factor
|
|
US5106733A
(en)
*
|
1987-06-25 |
1992-04-21 |
Immunex Corporation |
Bovine granulocyte-macrophage colony stimulating factor
|
|
WO1989010403A1
(en)
*
|
1988-04-21 |
1989-11-02 |
Medvet Science Pty. Ltd. |
Human gm-csf variants
|
|
WO1991002063A1
(en)
*
|
1989-08-11 |
1991-02-21 |
Amrad Corporation Limited |
Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
|
|
EP0711829A3
(en)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Recombinant alphavirus vector
|
|
EP0791061A4
(en)
*
|
1994-03-04 |
1998-07-15 |
Ludwig Inst Cancer Res |
TARGET GENE BREAKING ANIMALS
|
|
ATE386811T1
(de)
|
1996-04-05 |
2008-03-15 |
Novartis Vaccines & Diagnostic |
Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
|
|
CA2266656A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
|
CN1269805A
(zh)
*
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
|
WO1999017798A1
(en)
|
1997-10-02 |
1999-04-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
EP1980617A1
(en)
|
1998-12-31 |
2008-10-15 |
Novartis Vaccines and Diagnostics, Inc. |
Improved expression of HIV polypeptides and production of virus-like particles
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
EP1150666B1
(en)
*
|
1999-02-12 |
2009-10-28 |
Washington University |
Gm-csf for the treatment of crohn's disease
|
|
SG143058A1
(en)
*
|
2000-08-11 |
2008-06-27 |
Favrille Inc |
Method and composition for altering a t cell mediated pathology
|
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
|
CA2452015C
(en)
|
2001-07-05 |
2012-07-03 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US20030198621A1
(en)
|
2001-07-05 |
2003-10-23 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
|
JP2006500905A
(ja)
|
2002-02-13 |
2006-01-12 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
ヒト化ｇｍ−ｃｓｆ抗体
|
|
WO2003093417A2
(en)
|
2002-05-01 |
2003-11-13 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
|
GB0210741D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Medical Res Council |
Methods of therapy
|
|
GB0224415D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Medical Res Council |
Compositions
|
|
AU2004269320B2
(en)
|
2003-06-20 |
2009-12-24 |
Protein Sciences Corporation |
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
|
|
EP2266602A3
(en)
|
2004-11-01 |
2011-08-10 |
Novartis Vaccines and Diagnostics, Inc. |
Combination approaches for generating immune responses
|
|
GB0524103D0
(en)
|
2005-11-26 |
2006-01-04 |
Medical Res Council |
Healing
|
|
RS55526B1
(sr)
|
2006-02-08 |
2017-05-31 |
Morphotek Inc |
Antigenski gm-csf peptidi i antitela gm-csf
|
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
|
AU2010307075B2
(en)
|
2009-10-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Granulysin in immunotherapy
|
|
WO2012093258A2
(en)
|
2011-01-05 |
2012-07-12 |
Imperial Innovations Limited |
Treatment and screening
|
|
US9732144B2
(en)
|
2012-07-05 |
2017-08-15 |
Ohio State Innovation Foundation |
Infectious bursal disease (IBDV) vaccine compositions
|
|
CN108348593B
(zh)
|
2015-08-31 |
2022-08-16 |
泰克诺瓦克斯股份有限公司 |
基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
|
|
WO2017118866A1
(en)
|
2016-01-08 |
2017-07-13 |
Replimune Limited |
Engineered virus
|
|
WO2017180770A1
(en)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
|
JP7382230B2
(ja)
|
2016-10-17 |
2023-11-16 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組み換えウイルスレプリコン系及びその使用
|
|
BR112019011661A2
(pt)
|
2016-12-05 |
2020-01-07 |
Synthetic Genomics, Inc. |
Composições e métodos para aumentar expressão de gene
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
|
US11020476B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
KR20200111729A
(ko)
|
2018-01-19 |
2020-09-29 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
|
|
US12331076B2
(en)
|
2018-10-08 |
2025-06-17 |
Janssen Pharmaceuticals, Inc. |
Alphavirus-based replicons for administration of biotherapeutics
|